Search

Search Constraints

You searched for: Author/Creator Hrycaj, Pawel

Search Results

1. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Issue 3 (13th September 2016)

2. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Issue 10 (16th May 2013)

3. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Issue 10 (16th May 2013)

4. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Issue 6 (25th January 2016)

5. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. Issue 6 (18th August 2018)

6. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. (10th June 2019)

7. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Issue 10 (5th June 2017)

8. Interleukin‐17 and interleukin‐23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis. (28th January 2014)

9. Interleukin‐17 and interleukin‐23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis. (28th January 2014)

10. Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Issue 2 (28th January 2017)